With sequence data for hundreds of advanced breast cancer samples, investigators identified genetic alterations shared with — and distinct from — those in primary tumors.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
The researchers described gut microbial diversity and composition differences in metastatic melanoma patients who did or did not respond to immunotherapy.
Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.
The firm has launched a yearly subscription program that includes quarterly blood tests to look for genetic and proteomic signs of metastasis or cancer recurrence.
